We can see the bid price is slowly but steadily moving up, indicating that there is a sense of urgency in the buyers.
Let's wait for market to re-rate it when PTX announces licensing deal or phase 1B/2 results from any of the PTX200 clinical trials. $1 may not be that difficult when herds come.
